ArticleOpen heart2026
Transapical epicardial temporary pacemaker lead implantation in patients with transapical TAVI.
Article in Open heart, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to evaluate the safety and efficacy of transapical epicardial temporary pacemaker lead implantation compared with the conventional transvenous approach in patients undergoing transapical transcatheter aortic valve implantation (TAVI).
methodsIn this single-centre retrospective study, 399 patients who underwent transapical TAVI between December 2018 and August 2024 were included. Of these, 298 received transapical epicardial temporary pacing leads and 101 received transvenous leads. Primary outcomes included pacemaker-related cardiac tamponade, valve displacement and mortality. Secondary outcomes encompassed perioperative complications, permanent pacemaker implantation and postoperative adverse events.
resultsNo cases of cardiac tamponade, valve displacement or mortality related to temporary pacing were observed in either group. Poor lead contact occurred in one patient (0.3%) in the transapical group versus three patients (3.0%) in the transvenous group (p=0.05). Postoperative permanent pacemaker implantation was required in 12 transapical patients (4.0%) and three transvenous patients (3.0%, p=0.86).
conclusionTransapical epicardial temporary pacing is a safe and effective alternative to transvenous pacing during transapical TAVI, with comparable complication rates and potential technical benefits. Further randomised studies are warranted to validate these findings and explore long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.